Frequently Asked Questions

General Questions

What are peptides?

Peptides are short chains of amino acids (typically 2 to approximately 50) linked by peptide bonds. They are smaller than proteins but larger and more complex than most conventional drug molecules. The human body naturally produces thousands of peptides that serve as hormones, neurotransmitters, growth factors, and antimicrobial agents. Examples of natural peptides include insulin (which regulates blood sugar), oxytocin (which influences social bonding), endorphins (which modulate pain), and GLP-1 (which regulates appetite and insulin secretion). For a comprehensive overview, see our What Are Peptides? guide.

How are peptides different from steroids?

Peptides and steroids are fundamentally different types of molecules. Steroids are lipid-based compounds derived from cholesterol (e.g., testosterone, estrogen, cortisol). They are fat-soluble and cross cell membranes to bind intracellular receptors, directly influencing gene expression. Peptides are chains of amino acids that are generally water-soluble and cannot cross cell membranes. They bind to receptors on the cell surface and work through intracellular signaling cascades. While both can affect processes like growth, metabolism, and inflammation, their mechanisms, side effect profiles, and regulatory status are distinct.

How are peptides different from proteins?

The distinction is primarily one of size. Peptides are generally defined as chains of 2 to approximately 50 amino acids, while proteins are longer. Proteins fold into complex three-dimensional structures critical to their function, whereas peptides are typically more flexible and less structurally complex. Many proteins function as enzymes, structural components, or antibodies, while peptides tend to function as signaling molecules. The boundary is not sharp -- insulin (51 amino acids) is often called a peptide despite being at the protein threshold.

What do peptides do in the body?

Peptides serve as signaling molecules that regulate virtually every physiological system. Key roles include:

• Hormonal regulation: Insulin controls blood sugar; GLP-1 regulates appetite; vasopressin controls water balance; ACTH triggers cortisol release
• Neurotransmission: Endorphins and enkephalins modulate pain; substance P transmits pain signals; neuropeptide Y regulates appetite and stress
• Immune defense: Defensins and cathelicidins (like LL-37) kill bacteria and viruses as part of innate immunity
• Growth and repair: Growth hormone-releasing hormone (GHRH) stimulates growth hormone secretion; various growth factors promote tissue repair
• Cardiovascular regulation: Atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) regulate blood pressure and fluid balance

Safety Questions

Are peptides safe?

There is no single answer because "peptides" is a broad category encompassing thousands of different molecules. Safety depends on the specific peptide, the dose, the route of administration, the duration of use, and the individual's health status.

FDA-approved peptides (semaglutide, tirzepatide, octreotide, etc.) have well-characterized safety profiles established through rigorous clinical trials involving thousands of patients. Their known risks are documented in their prescribing information.

Research peptides (BPC-157, TB-500, Epithalon, DSIP, Semax, etc.) have not undergone comprehensive human safety testing. Their long-term effects in humans are unknown. Even if animal studies suggest they are well-tolerated, animals metabolize drugs differently than humans, and rare adverse effects only become apparent in large human populations.

Additional safety concerns with non-pharmaceutical peptides include unknown purity (contaminants, degradation products, endotoxins), inaccurate dosing, improper storage (many peptides degrade without refrigeration), and potential drug interactions that have never been studied.

What are common side effects of peptide therapies?

Side effects vary widely by peptide. Some well-characterized examples from FDA-approved peptides:

• GLP-1 receptor agonists (semaglutide, tirzepatide): Nausea, vomiting, diarrhea, constipation, abdominal pain (very common, especially during dose titration); injection site reactions; rare but serious: pancreatitis, gallbladder disease, potential thyroid concerns (medullary thyroid carcinoma in rodents)
• Growth hormone secretagogues: Increased hunger (ghrelin mimetics), water retention, joint pain, carpal tunnel symptoms, potential effects on blood glucose
• Melanocortin receptor agonists (bremelanotide): Nausea, flushing, headache, injection site reactions, transient blood pressure changes
• Antimicrobial peptides: Local irritation, potential for allergic reactions

For research peptides without formal human trials, the side effect profile is largely unknown.

Can peptides cause cancer?

This is an important concern that lacks a simple answer. Some peptides have theoretical pro-growth properties that could be concerning:

• Peptides that stimulate growth hormone or IGF-1 could theoretically promote the growth of existing tumors, though this has not been conclusively demonstrated for GH secretagogues at therapeutic doses
• Peptides that promote angiogenesis (new blood vessel formation) could theoretically support tumor vascularization
• GLP-1 receptor agonists caused medullary thyroid carcinoma in rodents, leading to a boxed warning, though this has not been observed in human studies to date

Conversely, some peptides have anti-cancer properties (certain antimicrobial peptides, somatostatin analogs used in neuroendocrine tumor treatment). The relationship between any specific peptide and cancer risk depends entirely on the peptide, the dose, and the patient's risk factors. This is an area of active research.

Are peptides addictive?

Most therapeutic peptides are not considered addictive in the traditional sense. They do not typically produce euphoria or the compulsive drug-seeking behavior associated with substances of abuse. However, some peptides that affect opioid receptors (e.g., endorphin analogs) could theoretically have dependence potential. Additionally, peptides that produce desirable effects (weight loss, improved body composition, enhanced recovery) may lead to psychological dependence, where users feel they cannot maintain results without continued use.

Legal and Regulatory Questions

Are peptides legal?

Legal status varies by peptide, country, and intended use:

Prescription peptide medications (semaglutide, insulin, octreotide, etc.) are legal when prescribed by a licensed healthcare provider for an approved or off-label indication.

Research peptides occupy a legal gray area in many countries. In the United States, peptides can legally be sold "for research purposes only, not for human consumption." Selling them for human use without FDA approval is illegal. Purchasing them for personal use falls into a poorly defined area that varies by jurisdiction.

Compounded peptides have faced increasing regulatory scrutiny. In 2023, the FDA added several peptides (including BPC-157) to a list of substances that cannot be used in compounding, citing insufficient safety data. This significantly restricted legal access to certain peptides in the US.

International variation: Regulations differ substantially between countries. Some peptides available over-the-counter in one country may be prescription-only or banned in another. Always verify the specific regulations in your jurisdiction.

What is the FDA's position on research peptides?

The FDA considers peptides sold for human consumption to be unapproved drugs unless they have gone through the formal approval process. The agency has taken enforcement action against companies marketing peptides with health claims, issuing warning letters and, in some cases, pursuing criminal charges.

In 2023-2024, the FDA increased scrutiny of peptides in several ways:

• Added multiple peptides to the Category 2 bulk drug substances list (cannot be used in compounding)
• Issued warnings about the risks of using compounded peptides
• Took action against companies selling peptides marketed as treatments for specific conditions

The FDA's fundamental position is that safety and efficacy must be demonstrated through clinical trials before a peptide can be marketed for human therapeutic use.

Are peptides banned in sports?

The World Anti-Doping Agency (WADA) prohibits many peptides for competitive athletes. The WADA Prohibited List includes:

• Growth hormone releasing factors: GHRH analogs (CJC-1295, sermorelin, tesamorelin), growth hormone secretagogues (ipamorelin, GHRP-2, GHRP-6, MK-677/ibutamoren)
• Growth hormone and its fragments: Including AOD-9604, hGH 176-191
• Peptide hormones: Erythropoietin (EPO), gonadotropins (hCG, LH)
• Metabolic modulators: GLP-1 receptor agonists are not currently prohibited but are on WADA's monitoring program
• Other: TB-500 (thymosin beta-4), BPC-157, and many other peptides fall under the broad prohibition of substances with "no current approval by any governmental regulatory health authority for human therapeutic use"

Athletes subject to WADA testing should assume that any non-approved peptide may lead to an anti-doping rule violation. The list is updated annually.

Do I need a prescription for peptides?

For FDA-approved peptide medications (semaglutide, tirzepatide, bremelanotide, etc.), yes -- a valid prescription from a licensed healthcare provider is required.

For research peptides, no prescription is required to purchase them as research chemicals, but they are not legally intended for human use. The lack of a prescription requirement does not mean they are safe or legal to self-administer.

Some healthcare providers at specialized clinics prescribe certain compounded peptides off-label, though the legality and availability of this practice has been significantly affected by recent FDA regulatory changes.

Administration Questions

How are peptides administered?

The most common routes of peptide administration are:

Subcutaneous injection (SC): The most common method for therapeutic peptides. A small needle is inserted into the fatty tissue just beneath the skin, typically in the abdomen, thigh, or upper arm. Most peptide medications come in pre-filled pens or require reconstitution from lyophilized (freeze-dried) powder.

Intramuscular injection (IM): Less common for peptides; delivers the peptide into muscle tissue for faster absorption.

Intravenous injection (IV): Used in clinical settings for certain peptides requiring immediate effect or precise dosing.

Oral: Traditionally very difficult for peptides due to enzymatic degradation and poor absorption. Oral semaglutide (Rybelsus) is a notable exception, using the absorption enhancer SNAC. Linaclotide and plecanatide are oral peptides that act locally in the gut.

Intranasal: Delivered as a nasal spray. Used for desmopressin, calcitonin, and oxytocin (research). Allows rapid absorption through the nasal mucosa and potential direct CNS access.

Topical: Applied to the skin. Limited to peptides targeting local effects (e.g., GHK-Cu in wound healing formulations). Most peptides are too large to penetrate intact skin effectively.

Why can't most peptides be taken orally?

The gastrointestinal tract is designed to break down proteins and peptides into individual amino acids for absorption. When a peptide is swallowed:

1. Stomach acid (pH 1.5-3.5) can denature the peptide's structure
2. Pepsin and other gastric proteases begin cleaving peptide bonds
3. Pancreatic proteases (trypsin, chymotrypsin, elastase) in the small intestine further degrade the peptide
4. Brush border peptidases on intestinal epithelial cells cleave remaining fragments
5. Even if some intact peptide reaches the intestinal wall, most peptides are too large and hydrophilic to cross the epithelial barrier
6. Any peptide that does absorb faces first-pass metabolism in the liver

The result is that oral bioavailability for most peptides is well under 1%. Pharmaceutical companies invest heavily in strategies to overcome this -- absorption enhancers, protease inhibitors, enteric coatings, nanoparticle encapsulation -- but oral delivery remains the exception for peptide drugs.

How should peptides be stored?

Most peptide medications and research peptides require careful storage:

• Lyophilized (freeze-dried) powder: Generally stable at room temperature for limited periods, but best stored refrigerated (2-8 degrees C) or frozen for long-term storage. Avoid repeated freeze-thaw cycles.
• Reconstituted solutions: Must be refrigerated and used within a limited timeframe (typically 2-4 weeks, depending on the peptide). Peptides in solution degrade faster than in lyophilized form.
• Pre-filled pens: Follow manufacturer instructions. Most require refrigeration before first use. Some (like semaglutide pens) can be kept at room temperature for a limited period after first use.
• General rules: Protect from light, avoid extreme temperatures, do not freeze reconstituted solutions (unless specifically indicated), use bacteriostatic water for reconstitution when available.

Improper storage can lead to peptide degradation, loss of potency, and formation of potentially harmful aggregates or degradation products.

Quality and Sourcing Questions

What is the difference between research-grade and pharmaceutical-grade peptides?

Pharmaceutical-grade peptides are manufactured under Good Manufacturing Practice (GMP) conditions, which include rigorous quality controls at every step of production. They must meet strict purity standards (typically greater than 98%), undergo testing for endotoxins, heavy metals, residual solvents, and microbial contamination, and have verified identity and potency. Batch-to-batch consistency is required. These are the peptides used in clinical trials and sold as approved medications.

Research-grade peptides are manufactured for laboratory use and may not meet pharmaceutical standards. While reputable research chemical suppliers maintain reasonable quality standards, there is significant variation in the market. Purity may range from 95% to greater than 99%, with the remaining percentage being impurities such as deletion sequences, truncated sequences, oxidized species, or residual reagents. There is no regulatory requirement for endotoxin testing, sterility, or pyrogen-free production.

The practical implication: Results from clinical trials using pharmaceutical-grade peptides cannot be assumed to apply to research-grade products. A contaminated or partially degraded peptide may not only fail to produce the expected effect -- it could cause adverse reactions unrelated to the peptide itself.

How can I verify peptide purity?

Third-party testing is the most reliable approach. Key analytical methods include:

• HPLC (High-Performance Liquid Chromatography): The standard method for assessing peptide purity. Separates the peptide from impurities based on their chemical properties. A purity percentage is reported.
• Mass spectrometry: Confirms the peptide's molecular weight matches the expected value, verifying identity. Does not directly measure purity.
• Amino acid analysis: Verifies the amino acid composition of the peptide.
• Endotoxin testing (LAL test): Tests for bacterial endotoxins, which can cause fever, inflammation, and in severe cases, septic shock. Critical for any injectable product.
• Sterility testing: Confirms the absence of viable microorganisms.

Some research peptide suppliers provide Certificates of Analysis (CoAs) with HPLC and mass spectrometry data. However, CoAs can be fabricated, and the batch you receive may not match the tested batch. Independent third-party testing services exist but add significant cost.

What is a compounding pharmacy?

A compounding pharmacy prepares customized medications by mixing, assembling, or altering ingredients to create a product tailored to a patient's specific needs. Compounding pharmacies have traditionally operated under Section 503A of the Federal Food, Drug, and Cosmetic Act, which allows them to prepare medications based on individual prescriptions.

In the peptide context, compounding pharmacies have been a primary source of peptides like BPC-157, thymosin alpha-1, PT-141, and others -- prepared as injectable formulations based on physician prescriptions. However, recent FDA actions have significantly restricted which peptides can be compounded, citing the lack of sufficient safety data for many popular peptides.

503A pharmacies compound based on individual prescriptions and are regulated primarily by state pharmacy boards.

503B outsourcing facilities can compound larger batches without individual prescriptions and are subject to more stringent FDA oversight, including GMP requirements and FDA inspections.

Evidence and Research Questions

Are results from animal studies applicable to humans?

Animal studies provide valuable information about biological mechanisms, toxicity, and potential therapeutic effects, but they are not directly transferable to humans. Key reasons:

• Species differences: Mice and rats metabolize drugs differently than humans, have different receptor expressions, different immune systems, and different physiological parameters
• Translation failure rate: Approximately 90% of drugs that succeed in animal studies fail in human clinical trials
• Dose scaling: Converting animal doses to human equivalent doses is not straightforward and involves significant uncertainty
• Disease model limitations: Most animal disease models are artificially induced and do not perfectly replicate natural human diseases
• Reporting bias: Animal studies with positive results are more likely to be published, creating an overly optimistic picture

Animal studies are necessary and valuable first steps. They are not proof of efficacy in humans. When someone claims a peptide "works" based on animal studies alone, the accurate statement is that the peptide showed promise in animal models and warrants further investigation in humans.

Why do some peptides have so little research?

Several factors limit research on certain peptides:

• Patentability: Natural peptide sequences are difficult to patent. Without patent protection, pharmaceutical companies cannot recoup the enormous investment ($1-2 billion) required for clinical development. This creates a "valley of death" where promising natural peptides never undergo large-scale human trials.
• Funding priorities: Government research funding is limited and competitive. Novel peptides without strong preliminary data may not receive grants.
• Regulatory hurdles: The FDA approval process is designed for new drugs. Natural peptides that have been used informally do not have a sponsor willing to invest in the formal process.
• Geographic limitations: Some peptides were developed in countries (e.g., Russia) where the research infrastructure and publication practices differ from Western standards, limiting international recognition and follow-up studies.
• Commercial interest: Research tends to follow commercial incentives. Peptides with clear commercial potential attract more investment and research than those without.

How do I find studies on a specific peptide?

The primary databases for finding scientific research include:

• PubMed (pubmed.ncbi.nlm.nih.gov): The most comprehensive database of biomedical literature. Free to search. Covers most English-language journals and many international ones.
• Google Scholar (scholar.google.com): Broader search including books, conference proceedings, and preprints. Less curated but more comprehensive in coverage.
• ClinicalTrials.gov: Registry of clinical trials. Search by peptide name to find ongoing or completed human studies.
• Cochrane Library (cochranelibrary.com): Database of systematic reviews and meta-analyses. Highest-quality evidence summaries.

Search tips: Use the peptide's chemical name, generic name, and common abbreviations. Check for related peptides and analogs. Look for systematic reviews first, then individual RCTs, then animal studies.

About PeptideInsight

Does PeptideInsight sell peptides?

No. PeptideInsight is an educational resource only. We do not sell, distribute, recommend suppliers for, or profit from the sale of peptides or any related products. We have no financial relationships with peptide suppliers, compounding pharmacies, or pharmaceutical companies. Our goal is to provide accurate, evidence-based information.

Can I use this site to treat a medical condition?

No. PeptideInsight provides educational information only. Nothing on this site constitutes medical advice, a diagnosis, or a recommendation for treatment. Many peptides discussed here are not approved for human use and have unknown safety profiles. Always consult a qualified healthcare provider for medical decisions.

What does "evidence level" mean on your peptide pages?

Our evidence grading system rates the quality and quantity of scientific research behind each peptide claim. "Strong Evidence" means multiple human clinical trials exist with consistent results. "Preclinical Only" means the evidence is limited to animal or laboratory studies. See our Evidence Framework for complete details on how grades are assigned.

How often is your content updated?

We review peptide profiles as significant new research is published. The last update date is shown on each peptide page. Given the rapidly evolving nature of peptide research, we recommend also checking primary sources (PubMed, ClinicalTrials.gov) for the most current information. If you notice outdated information or errors, please let us know.

How can I report an error or suggest a correction?

Contact us at [email protected] with the specific page, the information you believe is incorrect, and the source supporting your correction. We appreciate contributions from readers who help us maintain accuracy and will credit corrections where appropriate.

Do you accept advertising or sponsored content?

No. PeptideInsight does not accept advertising, sponsored content, paid product placements, or affiliate links. Our editorial independence is essential to our mission of providing unbiased, evidence-based information.